Supplementary Figure S2. LPAR1/3 antagonist VPC32183 inhibits mESC hematopoietic differentiation. (A) Representative flow cytometry data for CD41 staining. EBs were treated with DMSO or 10 μM VPC32183 from day 2 to day 6, and analyzed by flow cytometry. (B) Dose effect of VPC32183 treatment on CD41+ cell percentage (n=5). (C) qPCR analyses of hematopoietic transcription factors (n=4). (D and E) Methylcellulose colony-forming cell assay (M3434). Primitive erythroid colonies were scored 6 days later (D) (n=4). Definitive colonies were scored 10 days later (E) (n=4). Insets show average distribution of hematopoietic colonies. (F) Flow cytometry data for Flk1 staining in day 4 EBs treated with H2O or 10 μM VPC32183 from day 2 to day 4. (G) Effect of VPC32183 on Flk1+ cell percentage (n=5). (H) qPCR analyses of hematopoietic and germ layer markers (n=4). Endoderm marker: lamb1; mesoderm marker: brachyury; Ectoderm marker: beta-tub3. (I) BL-CFC assay. Blast colonies were identified and scored by their distinctive morphology 4 days after cultured in BL-CFC medium (n=4). Data shown were means ± s.e.m., *p < 0.05, **p < 0.01, ***p < 0.001 versus the corresponding control.